Bernard Hirschel
Hirschel, Bernard.
VIAF ID: 211310400 (Personal)
Permalink: http://viaf.org/viaf/211310400
Preferred Forms
- 100 0 _ ‡a Bernard Hirschel
-
- 100 1 _ ‡a Hirschel, Bernard
- 100 1 _ ‡a Hirschel, Bernard
-
Works
Title | Sources |
---|---|
Human anti-smooth muscle antibodies, 1974(hdg. on PPC rept.: Hirschel, Bernard; usage: Bernard Hirschel) | |
Impact of occasional short interruptions of HAART on the progression of HIV infection: results from a cohort study | |
Impact of previous virological treatment failures and adherence on the outcome of antiretroviral therapy in 2007. | |
Impact of single nucleotide polymorphisms and of clinical risk factors on new‐onset diabetes mellitus in HIV‐infected individuals | |
The impact of transmission clusters on primary drug resistance in newly diagnosed HIV-1 infection | |
Imported cases of histoplasmosis | |
Improved sensitivity of an interferon-gamma release assay (T-SPOT.TB™) in combination with tuberculin skin test for the diagnosis of latent tuberculosis in the presence of HIV co-infection | |
Improved virological outcome in White patients infected with HIV-1 non-B subtypes compared to subtype B. | |
Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection | |
Increased incidence of sexually transmitted infections in Geneva, Switzerland | |
Increased mortality after a first myocardial infarction in human immunodeficiency virus-infected patients; a nested cohort study | |
The individualized genetic barrier predicts treatment response in a large cohort of HIV-1 infected patients | |
Infectious diseases : a clinical short course | |
Infrequent replication of parvovirus B19 and erythrovirus genotypes 2 and 3 among HIV-infected patients with chronic anemia. | |
Initial treatment for HIV infection--an embarrassment of riches | |
Interruptions of cART limits CD4 T-cell recovery and increases the risk for opportunistic complications and death. | |
Is autovaccination dead? | |
Is unsafe sexual behaviour increasing among HIV-infected individuals? | |
Kidney light chain disease in patients with the acquired immunodeficiency syndrome | |
Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir | |
Long-term trends of HIV type 1 drug resistance prevalence among antiretroviral treatment-experienced patients in Switzerland | |
Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: Swiss HIV Cohort Study | |
Low bone mineral density, renal dysfunction, and fracture risk in HIV infection: a cross-sectional study | |
Low human immunodeficiency virus envelope diversity correlates with low in vitro replication capacity and predicts spontaneous control of plasma viremia after treatment interruptions | |
Micro-structural brain alterations in aviremic HIV+ patients with minor neurocognitive disorders: a multi-contrast study at high field | |
Modeling the influence of APOC3, APOE, and TNF polymorphisms on the risk of antiretroviral therapy-associated lipid disorders | |
Molecular epidemiology reveals long-term changes in HIV type 1 subtype B transmission in Switzerland | |
Nadir CD4 count and monthly income predict cervical squamous cell abnormalities in HIV-positive women in a resource-limited setting. | |
Neurocognitive impairment in patients randomized to second-line lopinavir/ritonavir-based antiretroviral therapy vs. lopinavir/ritonavir monotherapy. | |
["The new Center will allow the professionalization of patient-oriented clinical research". Interview by Marina Casselyn, Michael Balavoine, Kiefer Bertrand]. | |
New drugs, old drugs - dear drugs, cheap drugs | |
No longitudinal mitochondrial DNA sequence changes in HIV-infected individuals with and without lipoatrophy | |
L-ornithine alpha-ketoglutarate in HIV infection: effects on muscle, gastrointestinal, and immune functions | |
Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load | |
Predicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era | |
Predictors of optimal viral suppression in patients switched to abacavir, lamivudine, and zidovudine: the Swiss HIV Cohort Study | |
Quantifiable cytotoxic T lymphocyte responses and HLA-related risk of progression to AIDS | |
Questions about the antimalarial amodiaquine | |
Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir | |
A randomized crossover study to compare efavirenz and etravirine treatment. | |
A randomized trial of simplified maintenance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection | |
Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission | |
Relevance of HIV-1-specific CD4+ helper T-cell responses during structured treatment interruptions in patients with CD4+ T-cell nadir above 400/mm3. | |
Replicative phenotyping adds value to genotypic resistance testing in heavily pre-treated HIV-infected individuals--the Swiss HIV Cohort Study | |
Residual HIV-specific CD4 and CD8 T cell frequencies after prolonged antiretroviral therapy reflect pretreatment plasma virus load | |
Risk of influenza-like illness in an acute health care setting during community influenza epidemics in 2004-2005, 2005-2006, and 2006-2007: a prospective study | |
Rivastigmine for HIV-associated neurocognitive disorders: a randomized crossover pilot study | |
The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study | |
The role of compartment penetration in PI-Monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) Trial | |
The role of migration and domestic transmission in the spread of HIV-1 non-B subtypes in Switzerland | |
Role of retroviral restriction factors in the interferon-α-mediated suppression of HIV-1 in vivo | |
Safety and efficacy of once-daily nevirapine dosing: a multicohort study | |
Saquinavir trough concentration before and after switching NRTI to tenofovir in patients treated with once-daily saquinavir hard gel capsule/ritonavir 1600 mg/100 mg. | |
Screening and isolation to control meticillin-resistant Staphylococcus aureus: sense, nonsense, and evidence | |
Severe leptospirosis with multiple organ failure successfully treated by plasma exchange and high-volume hemofiltration | |
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score. | |
Le sida : guide du praticien : diagnostic, prise en charge, traitement | |
Small Dense Lipoproteins, Apolipoprotein B, and Risk of Coronary Events in HIV-Infected Patients on Antiretroviral Therapy | |
Stable partnership and progression to AIDS or death in HIV infected patients receiving highly active antiretroviral therapy: Swiss HIV cohort study | |
Structured treatment interruptions in HIV infection: benefit or disappointment? | |
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection | |
Substitution for protease inhibitors in HIV therapy | |
Successful efavirenz dose reduction guided by therapeutic drug monitoring. | |
Supersensitive Viral Load Assay in Predicting CD4-Guided Treatment Failure | |
Supervised interruptions of antiretroviral therapy | |
Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study | |
Switching from protease inhibitors to efavirenz: differences in efficacy and tolerance among risk groups: a case-control study from the Swiss HIV Cohort | |
Systemic antibody responses to gut commensal bacteria during chronic HIV-1 infection | |
Topical tacrolimus for effective treatment of eosinophilic folliculitis associated with human immunodeficiency virus infection | |
The trap: professional exposure to human immunodeficiency virus antibody negative blood with high viral load | |
Treatment modification in human immunodeficiency virus-infected individuals starting combination antiretroviral therapy between 2005 and 2008. | |
Treatment of Clostridium difficile infection in a French university hospital | |
Tuberculous Cutaneous Ulcers Associated with Miliary Tuberculosis in an Elderly Woman | |
Unsafe sex and increased incidence of hepatitis C virus infection among HIV-infected men who have sex with men: the Swiss HIV Cohort Study | |
Unusual primary HIV infection with colonic ulcer complicated by hemorrhagic shock: a case report | |
A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients | |
Viral resuppression and detection of drug resistance following interruption of a suppressive non-nucleoside reverse transcriptase inhibitor-based regimen | |
Virological and immunological responses to efavirenz or boosted lopinavir as first-line therapy for patients with HIV. | |
Weight-losing HIV-infected patients on recombinant human growth hormone for 12 wk: a national study |